Abstract： Objective： To observe the clinical effect of Qishi Yishen Prescription combined with Piperazine Ferulate on chronic glomerulonephritis（ CGN） and its effect on podocyte marker levels. Methods：A total of 88 cases of CGN patients admitted to Hangzhou Xiaoshan District Hospital of Chinese Medicine from July 2021 to July 2023 were divided into the western medicine group and the combined Chinese and western medicine group according to random number method，with 44 cases in each group. The western medicine group was treated with Piperazine Ferulate，and the combined Chinese and western medicine group was treated with Qishi Yishen Prescription combined with Piperazine Ferulate. Kidney function-related indexes [blood urea nitrogen （BUN），serum creatinine （SCr），24-hour urine protein （24 h-Upro）]，podocyte markers [urinary transmembrane protein B7-1（B7-1） and podocalyxin （PCX）]， inflammatory factors [interleukin-6 （IL-6），tumor necrosis factor-α （TNF-α）]，and clinical effects were compared between the two groups. Results： The total effective rate was 97.73% （43/44） in the combined Chinese and western medicine group and 81.82% （36/44） in the western medicine group， with a significant difference between the two groups（ P＜0.05）. After treatment，the levels of BUN，Scr，and 24 h-Upro in serum in the two groups were decreased when compared with those before treatment （P＜0.05），and the levels in the combined Chinese and western medicine group were lower than those in the western medicine group （P＜0.05）. After treatment，the levels of urinary B7-1 and PCX in the two groups were decreased when compared with those before treatment （P＜0.05）， and the levels in the combined Chinese and western medicine group were lower than those in the western medicine group （P＜0.05）. After treatment， the levels of IL-6 and TNF- α in the two groups were decreased when compared with those before treatment （P＜0.05），with lower levels in the combined Chinese and western medicine group compared to the western medicine group （P＜0.05）. Conclusion：Qishi Yishen Prescription combined with Piperazine Ferulate can effectively improve kidney function and podocyte marker levels in CGN patients， reduce inflammatory responses， and enhance clinical effect.